Long‑Term Oxygen Therapy in Bronchiectasis: Evidence‑Based Recommendations

Guideline Scope and Evidence Level

• The British Thoracic Society does not provide bronchiectasis‑specific recommendations for long‑term oxygen therapy (LTOT) (Grade D, expert consensus)【1, 2, 3】.
• The 2025 European Respiratory Society bronchiectasis guideline does not address LTOT, reflecting the absence of disease‑specific trials and the need to extrapolate from other chronic respiratory diseases【4】.
• In chronic obstructive pulmonary disease, LTOT has Grade A evidence for survival benefit, but in bronchiectasis the recommendation remains Grade D due to lack of randomized data【2, 3, 5, 6】.

Physiological Basis

• The same physiological principles that justify LTOT in other chronic hypoxemic respiratory diseases (e.g., COPD, interstitial lung disease, cystic fibrosis) are applied to bronchiectasis【5, 6, 7】.

Eligibility Criteria

Primary Indication

• Resting arterial oxygen tension (PaO₂) ≤ 7.3 kPa (≈55 mmHg) on a stable clinical basis warrants initiation of LTOT; this threshold is extrapolated from interstitial lung disease and cystic fibrosis data【5, 6, 7】.

Secondary Indications

• Resting PaO₂ ≤ 8 kPa (≈60 mmHg) together with any of the following complications qualifies for LTOT:
  
  • Peripheral edema,
  • Polycythemia (hematocrit ≥ 55 %), or
  • Evidence of pulmonary hypertension on ECG or echocardiography【5, 6】.

Assessment Timing and Screening

• Patients must be clinically stable for ≥ 8 weeks after their last exacerbation before a formal LTOT assessment is performed【2】.
• At hospital discharge, oxygen may be prescribed only to individuals with resting SpO₂ ≤ 92 % who are breathless and unable to manage without supplemental oxygen; reassessment is required after achieving stability【2】.
• Referral for arterial blood‑gas (ABG) analysis is indicated when resting SpO₂ ≤ 92 %【2】.
• Consider referral when SpO₂ ≤ 94 % and clinical signs of peripheral edema, polycythemia, or pulmonary hypertension are present【2】.

Measurement Protocol

• Confirm LTOT eligibility with two ABG measurements performed at least 3 weeks apart【1】.
• After oxygen titration, repeat ABG to verify adequate oxygenation without inducing respiratory acidosis or worsening hypercapnia【1】.

Therapeutic Goals

• The primary aim of LTOT in bronchiectasis is to improve tissue oxygenation and prevent complications of chronic hypoxemia, especially the development of pulmonary hypertension【5, 6】.

Special Clinical Situations

Active Smoking

• LTOT can be prescribed to patients who continue to smoke, but the clinical benefit is limited; counseling should emphasize reduced efficacy and fire‑hazard risks【2】.

Hypercapnia

• Hypercapnia does not preclude LTOT when hypoxemic criteria are met. Target SpO₂ 88–92 % in hypercapnic patients and re‑check blood gases 30–60 minutes after oxygen initiation to monitor for rising PaCO₂ or falling pH【8】.

Frequent Exacerbators

• Patients with frequent exacerbations who cannot achieve an 8‑week stable period may require earlier LTOT assessment, with the understanding that LTOT may become unnecessary once stability is attained【2】.

Summary Table of Eligibility Criteria

All statements are derived from cited sources and reflect current expert consensus in the absence of bronchiectasis‑specific randomized trials.

Long‑Term Oxygen Therapy (LTOT): Indications, Assessment, and Clinical Pitfalls

Chronic Obstructive Pulmonary Disease (COPD)

• PaO₂ ≤ 7.3 kPa (≈55 mmHg) in stable disease warrants LTOT – Grade A evidence. 9
• PaO₂ ≤ 8 kPa (≈60 mmHg) with any of the following complications warrants LTOT – peripheral edema, polycythemia (hematocrit ≥ 55 %), or pulmonary hypertension – Grade A evidence. 9, 10, 11, 12
• Hypercapnia does not preclude LTOT when the above hypoxemic criteria are met – Grade B evidence. 9, 13
• Patients must be clinically stable for ≥ 8 weeks after an exacerbation before formal LTOT assessment. 13

Interstitial Lung Disease (ILD)

• PaO₂ ≤ 7.3 kPa warrants LTOT – Grade D evidence (extrapolated from COPD data). 9, 11
• PaO₂ ≤ 8 kPa with peripheral edema, polycythemia, or pulmonary hypertension also qualifies for LTOT – Grade D evidence. 9, 11

Cystic Fibrosis (CF)

• PaO₂ ≤ 7.3 kPa qualifies for LTOT – Grade D evidence (no disease‑specific trials). 14, 15
• PaO₂ ≤ 8 kPa together with peripheral edema, polycythemia, or pulmonary hypertension qualifies for LTOT – Grade D evidence. 14, 15

Pulmonary Hypertension (PH)

• PaO₂ ≤ 8 kPa qualifies for LTOT regardless of additional complications – Grade D evidence. 9, 14
• LTOT in PH is intended to improve tissue oxygenation and prevent progression of pulmonary hypertension, rather than to provide a survival benefit as in COPD. 12, 14

Advanced Cardiac Failure

• PaO₂ ≤ 7.3 kPa qualifies for LTOT – Grade D evidence (consensus‑based). 14, 15
• PaO₂ ≤ 8 kPa with peripheral edema, polycythemia, or evidence of pulmonary hypertension on imaging qualifies for LTOT – Grade D evidence. 14, 15

Neuromuscular or Chest‑Wall Disorders

• Non‑invasive ventilation (NIV) is the primary therapy for type 2 respiratory failure; LTOT may be added if hypoxemia persists despite NIV, especially when co‑existing airway disease or obesity is present. 9, 14, 11

Screening & Assessment Criteria

• SpO₂ ≤ 92 % at rest triggers arterial blood‑gas assessment for LTOT eligibility – Grade C evidence. 13
• SpO₂ ≤ 94 % may also trigger assessment when clinical signs of peripheral edema, polycythemia, or pulmonary hypertension are present – Grade C evidence. 13
• All measurements must be performed during clinical stability, defined as ≥ 8 weeks after the last exacerbation. 13

Clinical Pitfalls

Active Smoking

• LTOT can be prescribed to active smokers, but the clinical benefit is limited – Grade D evidence. 10, 16
• Patients should be counseled about reduced efficacy and increased safety risks when continuing to smoke while on LTOT. 10, 16

Acute Exacerbations

• LTOT should not be initiated during an acute exacerbation. 13
• If supplemental oxygen is required at hospital discharge, limit it to patients with SpO₂ ≤ 92 % who are breathless and cannot manage without oxygen; reassess after achieving stability. 13

All facts are derived from peer‑reviewed sources cited above; strength of evidence (Grade A‑D) is indicated where provided.